REFERENCES:

Bloom K et al. Comparison of HER-2/neu analysis using FISH and IHC when HercepTest® is scored using conventional microscopy and image analysis. Breast Cancer Res Treat 2000; No abstract available.

Bucher C et al. Automated, high-throughput tissue microarray analysis for assessing the significance of HER-2 involvement in breast cancer. Proc ASCO 2000;19: Abstract 2388.

Buehler H et al. Effective HER-2/neu diagnosis in breast cancer by a combination of immunohistochemistry and FISH. Proc ASCO 2000;19: Abstract 294.

Cooke T et al. HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol 2001;12(suppl 1):S23-S28. Abstract

Couturier J et al. Strong correlation between results of fluorescence in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (Her-2/neu) gene status in breast carcinoma. Mod Pathol 2000;12(11):1238- 1243. Abstract

Hatanaka Y et al. Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTest™ in breast carcinoma by image analysis. Pathol Int 2001;51(1):33-36. Abstract

Hayes DF et al. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B. Clin Cancer Res 2001;7:2703-2711. Abstract

Hoang MP et al. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 2000;113(6):852-9. Full-Text

Press MF et al. HER-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-4970. Abstract

Ridolfi RL et al. HER-2/neu testing in breast carcinoma: A combined immumohistochemical and fluorescence in situ hybridization approach. Mod Pathol 2000;13:866-873. Abstract

Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 1999;112 (suppl 1):S53-S67. Full-Text

Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol 2001;12 (suppl 1):S3-S8. Abstract

Schaller G et al. Current use of HER2 tests. Ann Oncol 2001;12 (suppl 1):S97-S100. Abstract

Simon R et al. Patterns of HER-2/neu amplification and over-expression in primary and metastatic breast cancer. J Natl Cancer Inst 2001;93:1141-1146. Abstract

Starr A et al. Comparison of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in determining HER-2/neu status in breast cancer patients. Proc ASCO 2000;19: Abstract 2610.

Tanner M et al. Chromogenic in situ hybridization: A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000;57:1467- 1472. Abstract

Thor A. HER2 - a discussion of testing approaches in the USA. Ann Oncol 2001;12(suppl 1):S101-S107. Abstract

Tubbs RR et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:2714-2721. Abstract

Vogel CL et al. Superior outcomes with Herceptin (trastuzumab) in fluorescence in situ hybridization (FISH)-selected patients. Proc ASCO 2001b;20: Abstract 86.

Wang S et al. Assessment of HER-2/neu status in breast cancer. Automated cellular imaging system (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol 2001;116(4):495-503. Full-Text

Yamauchi H et al. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334-2356. Abstract

Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648. Abstract.

Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722-2730. Abstract.

Uber KA, Nicholson BP, Thor AD, et al. A phase II trial of weekly docetaxel (D) and Herceptin (H) as first- or second-line treatment in HER2 over-expressing metastatic breast cancer [abstract]. Proc Annu Meet Am Soc Clin Oncol 2001;20. Abstract 1949.

Horton J. HER2 and trastuzumab in breast cancer. Cancer Control 2001; 8:103-11. Full-Text

Hung MC, Lau YK. Basic science of HER-2/neu: A review. Semin Onocl 1999;26(suppl 12):51-59. Abstract

Jacobs TW et al. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. Am J Clin Pathol 2000;13:251-258. Full-Text

Jacobs TW et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999;17:1974-1982. Abstract

Jacobs TW et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999b;17:1983-1987. Abstract

Kakar S et al. Comparison of PathVysion and INFORM fluorescence in situ hybridization kits for assessment of HER-2/neu status in breast carcinoma. Molecular Diagnosis 2000;5:193-197. Abstract

Lebeau A et al. HER-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001;19:354-363. Abstract

Mass RD et al. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials. Proc ASCO 2000;19: Abstract 291.

Mass RD et al. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc ASCO 2001;20: Abstract 291.

Ménard S et al. HER2 overexpression in various tumor types, focusing on its relationship to the development of invasive breast cancer. Ann Oncol 2001:12(suppl 1):S15-S19. Abstract

Namer M et al. Comparison of C-erb-B2 expression in 104 primary breast tumors and their metastases by two immunohistochemical tests. Proc ASCO 2000;19: Abstract 2577.

Onody P et al. Fluorescence in situ hybridization and immunohistochemical assays for HER-2/neu status determination. Application to node-negative breast cancer. Arch Pathol Lab Med 2001;125: 46-750. Abstract

Pauletti G et al. Detection and quantitation of HER-2/neu gene amplfication in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-71. Abstract

Pauletti G et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;21:3651-3664. Abstract

Persons DL et al. Quantitation of HER-2/neu and c-myc gene amplfication in breast carcinoma using fluorescence in situ hybridization. Mod Pathol 1997;10:720-727. Abstract

Press MF et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-2904. Abstract

Press MF et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-2777. Abstract

Back | Top of Page